Tumor Ablation Therapy Devices Market Report 2025

This Tumor Ablation Therapy Devices market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The tumor ablation therapy devices market size has grown rapidly in recent years. It will grow from $0.72 billion in 2024 to $0.83 billion in 2025 at a compound annual growth rate (CAGR) of 15%. The growth in the historic period can be attributed to cancer incidence, technological advancements, aging population, minimally invasive procedures.

The tumor ablation therapy devices market size is expected to see rapid growth in the next few years. It will grow to $1.44 billion in 2029 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to personalized medicine, combination therapies, ai and image-guided ablation, telemedicine and remote consultations, training and education. Major trends in the forecast period include advancements in ablation technologies, imaging guidance, robotic and navigation assistance, immuno-oncology integration, percutaneous and image-guided ablation.

The tumor ablation therapy devices market is experiencing growth driven by the increasing prevalence of cancer. Cancer is a leading cause of mortality, with approximately 1 in 6 deaths worldwide attributed to this disease. Tumor ablation therapy is a minimally invasive procedure widely used to treat various types of tumors, including those in the lung, liver, kidney, and bones. For example, in 2023, the American Cancer Society Inc., a US-based non-profit health organization, estimates that the US will see around 1,958,310 new cancer cases, an increase compared to the more than 1,918,030 new cancer cases in 2022. This procedure offers an effective treatment option, particularly for patients who have not responded to chemotherapy or radiotherapy, thus supporting the growth of the tumor ablation therapy devices market.

The rising demand for minimally invasive procedures is expected to propel the tumor ablation therapy devices market. Minimally invasive procedures involve specialized instruments and technology to minimize incisions, leading to less disruption to the patient's body. Tumor ablation therapy devices play a crucial role in these procedures by effectively destroying tumors while minimizing damage to surrounding tissues. For instance, in January 2023, Intuitive Surgical Inc., a US-based manufacturer of robotic products, reported that approximately 1,875,000 surgical procedures were performed using da Vinci surgical systems in 2022, marking an 18% increase from the roughly 1,594,000 procedures conducted in 2021. Therefore, the growing demand for minimally invasive procedures is expected to drive the tumor ablation therapy devices market's growth.

Major companies in the tumor ablation therapy devices market are focusing on technological advancements to improve procedure efficiency, safety, reduce radiation exposure, shorten learning curves, and enhance patient outcomes. For instance, Compal Electronics, a Taiwan-based electronics manufacturing company, introduced AblatePal in April 2023, a new radiofrequency ablation (RFA) system designed for the percutaneous, intraoperative coagulation and ablation of soft tissue, particularly non-resectable liver lesions. It employs electrical resistance to generate heat energy in the targeted tissue, resulting in its eradication. This system has applications in therapeutic medical devices, especially for cancer treatment.

Major companies are committed to developing minimally invasive therapies to gain a competitive edge in the market. Minimally invasive therapy is highly effective for tumor ablation, providing precise treatment with minimal disruption to surrounding tissues. For example, in August 2023, Francis Medical Inc., a US-based provider of minimally invasive treatment solutions for prostate, kidney, and bladder cancer, received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Vanquish minimally invasive water vapor ablation therapy. This designation aims to expedite the device's development and regulatory evaluation, potentially ensuring quicker patient access. The Vanquish system employs sterile water's thermal energy for precise cancer tissue treatment through a straightforward transurethral procedure, minimizing the risk of severe side effects associated with alternative prostate cancer therapies.

In August 2022, Imagin Medical, a Canada-based urologic oncology company, acquired the enCAGE Coil Precision Ablation System for Prostate Cancer from TROD Medical NV for $2.5 million. This acquisition strengthens Imagin's position as a urologic oncology company and broadens its portfolio in the field of prostate cancer. TROD Medical NV is a Belgium-based medical device company.

Tumor ablation therapy devices are minimally invasive tools used to treat tumors, typically in the kidney, liver, and lung. These devices utilize different techniques to target and destroy cancerous cells while safeguarding the surrounding healthy tissue.

The primary technologies utilized in tumor ablation therapy devices include radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and other related methods. Irreversible electroporation (IRE) is an innovative technique within tumor ablation therapy, involving the application of micro to millisecond electrical pulses to undesired tissue, which results in the induction of cell necrosis through irreversible cell membrane permeabilization. Treatments using these devices can take the form of surgical procedures, laparoscopic interventions, or percutaneous methods, and are applicable in the treatment of various types of cancer, including kidney, liver, breast, lung, prostate, and others. The end-users of tumor ablation therapy devices encompass hospitals, oncology clinics, and other healthcare facilities.

The tumor ablation therapy devices market research report is one of a series of new reports that provides tumor ablation therapy devices market statistics, including tumor ablation therapy devices industry global market size, regional shares, competitors with a tumor ablation therapy devices market share, detailed tumor ablation therapy devices market segments, market trends and opportunities, and any further data you may need to thrive in the tumor ablation therapy devices industry. This tumor ablation therapy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the tumor ablation therapy devices market include Galil Medical Inc., Misonix Inc., HealthTronics Inc., AngioDynamics Inc., Boston Scientific Corporation, Medtronic PLC, EDAP TMS S.A., NeuWave Medical Inc., BVM Medical Limited, Erbe Elektromedizin GmbH, AtriCure Inc., Theraclion, INTIO Inc., BIOTRONIK SE & Co. KG, Olympus Corporation, Stryker Corporation, Merit Medical Systems Inc., Insightec Ltd., Terumo Corporation, Smith & Nephew PLC, Monteris Medical Corporation, IceCure Medical Ltd., Profound Medical Inc., Alpinion Medical Systems Co. Ltd., Sonacare Medical, Hologic Inc., Endocare Inc., Integra LifeSciences Corporation, Bovie Medical Corporation.

North America was the largest region in the tumor ablation therapy devices market in 2024. Asia-Pacific was the second largest region in the tumor ablation therapy devices market. The regions covered in the tumor ablation therapy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tumor ablation therapy devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tumor ablation therapy devices market consists of sales of radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and others that are used for tumor ablation therapies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.